4.7 Article

Constitutional isomers of Reactive Blue 2 -: selective P2Y-receptor antagonists?

Journal

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 38, Issue 3, Pages 303-312

Publisher

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/S0223-5234(02)01449-6

Keywords

Reactive Blue 2; Cibacron Blue 3GA; P2-receptor antagonist; rat vas deferens; guinea-pig taenia coli; P2X(1)-receptor; P2Y(1)-like-receptor

Ask authors/readers for more resources

The anthraquinone derivative Reactive Blue 2 (RB 2) is one of the most widely used P2-receptor antagonists, still claimed to be P2Y-selective. RB 2 is defined as a mixture of two constitutional isomers and commercially available in different identity and purity. A sample of RB 2, offered for sale by RBI, purchased from Biotrend, Koln, Germany, was chromatographically purified and identified by H-1- and C-13-NMR studies as a 35:65 mixture of the terminal ring F meta and para constitutional isomers. The two constitutional isomers of RB 2 were synthesised and tested alongside with the ortho isomer Cibacron Blue 3GA (CB 3GA) on contractions of the,rat vas deferens (RVD) elicited by alpha,beta-methylene ATP (alpha,beta-MeATP), mediated by P2X(1)-receptors, and relaxations of the carbachol-precontracted guinea pig taenia coli elicited by adenosine 5'-O-(2-thiophosphate) (ADPOS), mediated by P2Y(1)-like-receptors. All compounds inhibited the alpha,beta-MeATP induced contraction of the RVD and the ADPbetaS induced relaxation of the carbachol precontracted guinea-pig taenia coli. The IC50-values at P2X(1)-R were 9.1 muM for CB 3GA, 28.4 muM for RB 2, 19.7 muM for RB 2 meta, and 35.5 muM for RB 2 para. The IC50-values at P2Y(1)-like-R were 17.4 muM for CB 3GA, 7.7 muM for RB 2, 12.0 muM for RB 2 meta, and 2.6 muM for RB 2 para. The results clearly show that neither RB 2 as a mixture nor the pure ortho and meta isomer are P2Y(1)-like- versus P2X(1)-selective antagonists. In contrast the pure para-isomer of RB 2 is a moderately P2Y(1)-like- versus P2X(1)-selective antagonist. (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available